Investigational drug · Phase 2
GSK3174998
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Multiple Myeloma.
Phase 2Last checked: Nov 20, 2026Latest source record: May 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
5
Any phase or sponsor naming "GSK3174998"
First trial start
2019
Oct 7, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "GSK3174998", any sponsor or status.
Conditions studied
As listed on its trial records.
- Multiple Myeloma
Approved drugs for the same conditions: Multiple myeloma · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "GSK3174998" as an intervention, largest first.
GlaxoSmithKlineGSK (GSK)
NCT02723955 · 829 participants · Start Jun 23, 2016 · Primary completion Jul 5, 2023
Drug: feladilimab (GSK3359609); GSK3174998 and 9 more · For: Neoplasms
Sites: Duarte, California; Los Angeles, California; Sarasota, Florida · 28 sites in all
- Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)Pivotal-lookingActive, not recruiting
GlaxoSmithKlineGSK (GSK)
NCT04126200 · 208 participants · Start Oct 7, 2019 · Primary completion Apr 17, 2025
Drug: Belantamab mafodotin; GSK3174998 and 7 more · For: Multiple Myeloma
Sites: Atlanta, Georgia; Indianapolis, Indiana; Boston, Massachusetts · 38 sites in all
- GSK3174998 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors (ENGAGE-1)Completed
GlaxoSmithKlineGSK (GSK)
NCT02528357 · 141 participants · Start Sep 11, 2015 · Primary completion Apr 29, 2020
Drug: GSK3174998; Pembrolizumab · For: Neoplasms
Sites: Boston, Massachusetts; New York, New York; Nashville, Tennessee · 8 sites in all
- Study of a Combination of GSK1795091 and Immunotherapies in Subjects With Advanced Solid TumorsCompleted
GlaxoSmithKlineGSK (GSK)
NCT03447314 · 54 participants · Start Mar 26, 2018 · Primary completion Jul 1, 2020
Drug: GSK1795091; GSK3174998 and 2 more · For: Neoplasms
Sites: Boston, Massachusetts; St Louis, Missouri; Dallas, Texas · 8 sites in all
GlaxoSmithKlineGSK (GSK)
NCT06160609 · 9 participants · Start Oct 7, 2019 · Primary completion Jan 9, 2023
Drug: Belantamab Mafodotin; GSK3174998 · For: Relapsed/Refractory Multiple Myeloma
Sites: Fitzroy, Australia; Toronto, Canada; Stockholm, Sweden
Newest research
PubMed records naming it or its code names, newest first.
- Impact of isotype on the mechanism of action of agonist anti-OX40 antibodies in cancer: implications for therapeutic combinations.
Willoughby JE, Dou L, Bhattacharya S, et al. · J Immunother Cancer 2024
- First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1).
Postel-Vinay S, Lam VK, Ros W, et al. · J Immunother Cancer 2023
- Manufacturing-dependent change in biological activity of the TLR4 agonist GSK1795091 and implications for lipid A analog development.
Steeghs N, Hansen AR, Hanna GJ, et al. · Clin Transl Sci 2022
- Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design.
Nooka AK, Weisel K, van de Donk NW, et al. · Future Oncol 2021
- OX40 agonists for cancer treatment: a patent review.
Cebada J, Perez-Santos M, Bandala C, et al. · Expert Opin Ther Pat 2021
Also in development for Multiple Myeloma
- EtentamigABBV-383, TNB-383BPhase 38 trials
AbbVie · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma, Amyloid Light Chain (AL) Amyloidosis
- BMS-986348CC-92480, mezigdomidePhase 37 trials
Bristol Myers Squibb · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma
- GR1803Velinotamig specified specified days., CLN-803Phase 37 trials
Genrix (Shanghai) Biopharmaceutical Co., Ltd. · Multiple Myeloma, Immune Thrombocytopenia (ITP), Warm Autoimmune Hemolytic Anemia (WAIHA)
- JNJ-79635322Ramantamig, BCMAxGPRC5DxCD3Phase 37 trials
Johnson & Johnson (Janssen) · Multiple Myeloma
- Cilta-celJNJ-68284528Phase 36 trials
Johnson & Johnson (Janssen) · Multiple Myeloma
- Anitocabtagene AutoleucelCART-ddBCMAPhase 34 trials
Gilead Sciences · Multiple Myeloma, Newly Diagnosed Multiple Myeloma
- CevostamabRO7187797Phase 34 trials
Roche (Genentech) · Multiple Myeloma
- IBI3003Phase 34 trials
Innovent Biologics (Suzhou) Co. Ltd. · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from GSK.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.